Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.

Cancer gene therapy - 1 Apr 2005

Ebert Oliver, Harbaran Sonal, Shinozaki Katsunori, Woo Savio L C

Abstract excerpt

In view of the limited success of available treatment modalities for metastatic breast cancer, alternative and complementary strategies need to be developed. Oncolytic vesicular stomatitis virus (VSV) is a promising novel therapeutic agent for the treatment of cancer. The aim of this study was to evaluate the potential of recombinant VSV containing the M51R mutation in the matrix (M) protein gene administered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Galactosides
Share to Gene Transfer Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lac Operon

Share to Neoplasm Transplantation

Share to Neoplasms, Experimental

Share to Vesicular stomatitis Indiana virus

Share to Viral Matrix Proteins

Source

Identifiers

PMID: 15565179
DOI: 10.1038/sj.cgt.7700794

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.PMID 15565179Read ↗

Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.Semantic proximity Read ↗

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Semantic proximity Read ↗

The Novel Oncolytic Herpes Simplex Virus Type-1 (HSV-1) Vaccine Strain VC2 Constitutively Expressing GM-CSF Causes Increased Intratumoral T Cell Infiltration and Inhibition of Tumor Metastasis in the 4T1/Balb/c Mouse Model of Stage Four Breast CancerSemantic proximity Read ↗

Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.Semantic proximity Read ↗

Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virusSemantic proximity Read ↗

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.Semantic proximity Read ↗

Treatment with M51R Vesicular Stomatitis Virus Induces Clonal Antitumor CD8+ T Cell Expansion in Colon CancerSemantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic VectorSemantic proximity Read ↗

Oncolytic Activity of Vesicular Stomatitis Virus Is Effective against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of ApoptosisSemantic proximity Read ↗

Rapid Pathogenesis Induced by a Vesicular Stomatitis Virus Matrix Protein Mutant: Viral Pathogenesis Is Linked to Induction of Tumor Necrosis Factor AlphaSemantic proximity Read ↗

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.Semantic proximity Read ↗

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.